Source comparison
CJC-1295 No DAC & Ipamorelin vs Other GHRH and GHRP Combinations
Understanding why CJC-1295 no DAC & Ipamorelin dual GHRH + GHRP synergy is the preferred combination in contemporary research requires comparing it to alternative GHRH and GHRP pairings. The table below summarizes the key differentiators. CJC-1295 no DAC + Ipa
This comparison does not assign a generated winner or score.
- Understanding why CJC-1295 no DAC & Ipamorelin dual GHRH + GHRP synergy is the preferred combination in contemporary research requires comparing it to alternative GHRH and GHRP pairings. The table below summarizes the key differentiators.
- CJC-1295 no DAC + Ipamorelin
- ~30 minutes
- High (minimal prolactin/cortisol)
- Minimal
- 20–40 min, duration 90–120 min
- Most selective synergy. Potent GH release without unwanted prolactin or cortisol spikes. Ideal for protocols prioritizing clean GH stimulation.
- Sermorelin + Ipamorelin
- ~10 minutes (very short)
- High
- 20–40 min, duration 60–90 min
- Similar selectivity to CJC-1295 no DAC + Ipamorelin but shorter GHRH half-life requires more frequent dosing or higher doses to maintain receptor occupancy throughout Ipamorelin's activity window.
- CJC-1295 no DAC + GHRP-6
- Moderate (increases appetite, mild prolactin)
- Moderate (ghrelin mimetic effects)
- Stronger GH release than Ipamorelin but with appetite stimulation and modest prolactin elevation. Useful when appetite increase is desired, problematic when it's not.
- Sermorelin + GHRP-2
- ~10 minutes
- Low (elevates prolactin and cortisol)
- Significant
- Potent GH release but least selective. Cortisol and prolactin elevation can interfere with metabolic and recovery endpoints in long-term protocols.
- CJC-1295 with DAC + Ipamorelin
- 6–8 days (sustained elevation)
- Continuous elevation for days
- Eliminates pulsatility. Sustained GH elevation may cause receptor desensitization and blunts the physiological benefits of pulsatile secretion. Not ideal for long-term use.
- The CJC-1295 no DAC & Ipamorelin dual GHRH + GHRP synergy strikes the optimal balance: the 30-minute half-life of CJC-1295 no DAC is long enough to overlap fully with Ipamorelin's activity window, creating robust synergy, but short enough to preserve pulsatility and avoid chronic receptor desensitization. Ipamorelin's selectivity ensures that GH release occurs without the prolactin, cortisol, or appetite-stimulating side effects seen with less selective GHRPs like GHRP-2 or GHRP-6. This combination is why the pre-mixed CJC1295 Ipamorelin 5MG 5MG formulation has become one of the most widely adopted stacks in growth hormone research protocols. It delivers maximal synergistic GH release with minimal off-target effects.